Neuroendocrine tumors (NETs) are a type of cancerous growth affecting cells that send hormones around the body. Pancreatic neuroendocrine tumors (PNETs) grow in the cells of the pancreas that produce ...
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...
Neuroendocrine cancer, a rare disease affecting hormone-making cells, tragically claimed the life of actor Irrfan Khan in 2020. These tumors can be slow-growing or aggressive, often presenting with ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee (ODAC) in ...
The latest update is out from Perspective Therapeutics ( (CATX) ).
The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area ...
Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback